This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-08-2689v1 69/10/4225    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Saito, S. Articles by Tomida, A. PubMed PubMed Citation Articles by Saito, S. Articles by Tomida, A.

Chemical Genomics Identifies the Unfolded Protein Response as a Target for Selective Cancer Cell Killing during Glucose Deprivation

¹ Cancer Chemotherapy Center, Japanese Foundation for Cancer Research; ² Biological Information Research Center, National Institute of Advanced Industrial Science and Technology, Tokyo, Japan and ³ Department of Food Science and Biotechnology, Kyungnam University, Masan, Korea

Requests for reprints: Akihiro Tomida, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-10-6 Ariake, Koto-ku, Tokyo 135-8550, Japan. Phone: 81-3-3570-0514; Fax: 81-3-3570-0484; E-mail: akihiro.tomida{at}jfcr.or.jp.

Key Words: glucose deprivation • unfolded protein response (UPR) • antidiabetic biguanides • endoplasmic reticulum stress • chemotherapy

Glucose deprivation, a cell condition that occurs in solid tumors, activates the unfolded protein response (UPR). A key feature of the UPR is the transcription program activation, which allows the cell to survive under stress conditions. Here, we show that the UPR transcription program is disrupted by the antidiabetic biguanides metformin, buformin, and phenformin depending on cellular glucose availability. These drugs inhibit production of the UPR transcription activators XBP1 and ATF4 and induce massive cell death during glucose deprivation as did the antitumor macrocyclic compound versipelostatin. Gene expression profiling shows remarkable similarity in the modes of action of biguanides and versipelostatin determined by the broad range of glucose deprivation-inducible genes. Importantly, during glucose deprivation, most of the biguanide suppression genes overlap with the genes induced by tunicamycin, a chemical UPR inducer. Gene expression profiling also identifies drug-driven signatures as a tool for discovering pharmacologic UPR modulators. Our findings show that disrupting the UPR during glucose deprivation could be an attractive approach for selective cancer cell killing and could provide a chemical genomic basis for developing UPR-targeting drugs against solid tumors. [Cancer Res 2009;69(10):4225–34]